<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chai S</submitter><funding>NIDDK NIH HHS</funding><pagination>789-800</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9419973</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>33(15-16)</volume><pubmed_abstract>Diabetes mellitus, caused by loss or dysfunction of the insulin-producing beta cells of the pancreas, is a promising target for recombinant adeno-associated virus (rAAV)-mediated gene therapy. To target potential therapeutic payloads specifically to beta cells, a cell type-specific expression control element is needed. In this study, we tested a series of rAAV vectors designed to express transgenes specifically in human beta cells using the islet-tropic rAAV-KP1 capsid. A small promoter, consisting of only 84 bp of the insulin core promoter was not beta cell-specific in AAV, but highly active in multiple cell types, including tissues outside the pancreas. A larger 363 bp fragment of the insulin promoter (INS) also lacked beta cell specificity. However, beta cell-specific expression was ach</pubmed_abstract><journal>Human gene therapy</journal><pubmed_title>Development of a Beta Cell-Specific Expression Control Element for Recombinant Adeno-Associated Virus.</pubmed_title><pmcid>PMC9419973</pmcid><funding_grant_id>U01 DK123608</funding_grant_id><pubmed_authors>Ackermann AM</pubmed_authors><pubmed_authors>Posey J</pubmed_authors><pubmed_authors>Grompe M</pubmed_authors><pubmed_authors>Kaestner KH</pubmed_authors><pubmed_authors>Hebrok M</pubmed_authors><pubmed_authors>Kim Y</pubmed_authors><pubmed_authors>Wakefield L</pubmed_authors><pubmed_authors>Chai S</pubmed_authors><pubmed_authors>Galivo F</pubmed_authors><pubmed_authors>Dorrell C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development of a Beta Cell-Specific Expression Control Element for Recombinant Adeno-Associated Virus.</name><description>Diabetes mellitus, caused by loss or dysfunction of the insulin-producing beta cells of the pancreas, is a promising target for recombinant adeno-associated virus (rAAV)-mediated gene therapy. To target potential therapeutic payloads specifically to beta cells, a cell type-specific expression control element is needed. In this study, we tested a series of rAAV vectors designed to express transgenes specifically in human beta cells using the islet-tropic rAAV-KP1 capsid. A small promoter, consisting of only 84 bp of the insulin core promoter was not beta cell-specific in AAV, but highly active in multiple cell types, including tissues outside the pancreas. A larger 363 bp fragment of the insulin promoter (INS) also lacked beta cell specificity. However, beta cell-specific expression was ach</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Aug</publication><modification>2025-04-04T20:33:06.384Z</modification><creation>2025-04-04T20:33:06.384Z</creation></dates><accession>S-EPMC9419973</accession><cross_references><pubmed>35297680</pubmed><doi>10.1089/hum.2021.219</doi></cross_references></HashMap>